Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11975889 | 1.00 | DDB1 (0.33) | DDB1CRBNCYP3A4 | |
| SCHEMBL11983950 | 1.00 | DDB1 (0.33) | DDB1CRBNCYP3A4 | |
| SCHEMBL13563487 | 0.96 | DDB1 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL3799932 | 0.96 | DDB1 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL13563489 | 0.95 | DDB1 (0.31) | DDB1CRBNCYP3A4 | |
| SCHEMBL11976188 | 0.95 | CYP3A4 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL3790122 | 0.95 | DDB1 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL3788175 | 0.95 | DDB1 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL11984248 | 0.94 | CYP3A4 (0.32) | DDB1CRBNCYP3A4 | |
| SCHEMBL3969380 | 0.94 | REN (0.33) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | DDB1 746/4885CRBN 2033/4885CYP3A4 826/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | DDB1 746/4885CRBN 2033/4885CYP3A4 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.